Install
- 31articles · 30d
- 1+ day agolatest article
- Aug 16, 2026earliest in window
- 100%with images
- 246avg words
- Business & Industrial 24
- Economy, Business & Finance 21
- Medical 21
- Science & Technology 9
- Finance & Business 6
- Health & Wellness 6
- Crime & Law 2
- Science & Nature 2
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Tyra Biosciences Phase II SURF302 results support LG IR NMIBC with dabogratinib
4+ day, 1+ hour ago (230+ words) The Pharma Letter - Tyra Biosciences Phase II SURF302 results support LG IR NMIBC with dabogratinib US clinical-stage biotech Tyra Biosciences (Nasdaq: TYRA) yesterday announced initial results from SURF302, its Phase II study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle…...
Solstice Oncology launches with $225 million to advance neoadjuvant CTLA-4 antibody
4+ day, 4+ hour ago (209+ words) The Pharma Letter - Solstice Oncology launches with $225 million to advance neoadjuvant CTLA-4 antibody USA-based Solstice Oncology has launched with a $225 million Series A financing to advance porustobart, a second-generation, Fc-enhanced CTLA-4 antibody, into neoadjuvant treatment of colon cancer. The round…...
Zentalis Pharmaceuticals
3+ week, 2+ day ago (588+ words) The Pharma Letter A clinical-stage biopharmaceutical company focused on WEE1 inhibition in biomarker-selected ovarian cancer, with its lead asset azenosertib approaching a pivotal registration-enabling data readout in 2026. Zentalis Pharmaceuticals discovers and develops small molecule therapeutics targeting fundamental biological pathways in cancer....